Value of 11C-choline PET and PET/CT in Patients with Suspected Prostate Cancer

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2006 Aug 26

PMID 16932935

Citations 57

Authors

Bernhard Scher

Michael Seitz

Wolfram Albinger

Reinhold Tiling

Michael Scherr

Hans-Christoph Becker

Michael Souvatzogluou

Franz-Josef Gildehaus

Hans-Jurgen Wester

Stefan Dresel

Affiliations

Soon will be listed here.

Abstract

Purpose: The value and limitations of (11)C-choline PET and PET/CT for the detection of prostate cancer remain controversial. The aim of this study was to investigate the diagnostic efficacy of (11)C-choline PET and PET/CT in a large group of patients with suspected prostate cancer.

Methods: Fifty-eight patients with clinical suspicion of prostate cancer underwent (11)C-choline PET (25/58, Siemens ECAT Exact HR+) or PET/CT (33/58, Philips Gemini) scanning. On average, 500 MBq of (11)C-choline was administered intravenously. Studies were interpreted by raters blinded to clinical information and other diagnostic procedures. Qualitative image analysis as well as semiquantitative SUV measurement was carried out. The reference standard was histopathological examination of resection specimens or biopsy.

Results: Prevalence of prostate cancer in this selected patient population was 63.8% (37/58). (11)C-choline PET and PET/CT showed a sensitivity of 86.5% (32/37) and a specificity of 61.9% (13/21) in the detection of the primary malignancy. With regard to metastatic spread, PET showed a per-patient sensitivity of 81.8% (9/11) and produced no false positive findings.

Conclusion: Based on our findings, differentiation between benign prostatic changes, such as benign prostatic hyperplasia or prostatitis, and prostate cancer is feasible in the majority of cases when image interpretation is primarily based on qualitative characteristics. SUV(max) may serve as guidance. False positive findings may occur due to an overlap of (11)C-choline uptake between benign and malignant processes. By providing functional information regarding both the primary malignancy and its metastases, (11)C-choline PET may prove to be a useful method for staging prostate cancer.

Citing Articles

The Evolving Role of F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer.

Shen K, Liu B, Zhou X, Ji Y, Chen L, Wang Q Front Oncol. 2021; 11:683793.

PMID: 34395251 PMC: 8358601. DOI: 10.3389/fonc.2021.683793.

Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [F]DCFPyL-PET: comparison to [F]fluorocholine-PET.

Yang D, Li F, Bauman G, Chin J, Pautler S, Moussa M EJNMMI Res. 2021; 11(1):2.

PMID: 33394284 PMC: 7782622. DOI: 10.1186/s13550-020-00735-w.

Dynamic 11C-Choline PET / CT for the primary diagnosis of prostate cancer.

Golan S, Nidam M, Bernstine H, Baniel J, Groshar D Int Braz J Urol. 2018; 44(5):900-905.

PMID: 30088719 PMC: 6237539. DOI: 10.1590/S1677-5538.IBJU.2018.0035.

Targeted 11C-choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy.

Lazzeri M, Lopci E, Lughezzani G, Colombo P, Casale P, Hurle R Eur J Hybrid Imaging. 2018; 1(1):9.

PMID: 29782590 PMC: 5954704. DOI: 10.1186/s41824-017-0011-1.

Anatomic and Molecular Imaging in Prostate Cancer.

Miller E, Salmasi A, Reiter R Cold Spring Harb Perspect Med. 2017; 8(3).

PMID: 28710256 PMC: 5830905. DOI: 10.1101/cshperspect.a030619.

References

Yu K, Scheidler J, Hricak H, Vigneron D, Zaloudek C, Males R . Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999; 213(2):481-8. DOI: 10.1148/radiology.213.2.r99nv26481. View

Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T . 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int. 2005; 74(3):214-20. DOI: 10.1159/000083551. View

Kurhanewicz J, Vigneron D, Hricak H, Parivar F, Nelson S, Shinohara K . Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology. 1996; 200(2):489-96. DOI: 10.1148/radiology.200.2.8685346. View

de Jong I, Pruim J, Elsinga P, Vaalburg W, Mensink H . Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003; 44(3):331-5. View

Qayyum A, Coakley F, Lu Y, Olpin J, Wu L, Yeh B . Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol. 2004; 183(4):1079-83. DOI: 10.2214/ajr.183.4.1831079. View

Wefer A, Hricak H, Vigneron D, Coakley F, Lu Y, Wefer J . Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000; 164(2):400-4. View

Swinnen J, Van Veldhoven P, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F . Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun. 2003; 302(4):898-903. DOI: 10.1016/s0006-291x(03)00265-1. View

Breeuwsma A, Pruim J, Jongen M, Suurmeijer A, Vaalburg W, Nijman R . In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005; 32(6):668-73. DOI: 10.1007/s00259-004-1741-4. View

Toth G, Lengyel Z, Balkay L, Salah M, Tron L, Toth C . Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol. 2004; 173(1):66-9. DOI: 10.1097/01.ju.0000148326.71981.44. View

10.

van Dorsten F, van der Graaf M, Engelbrecht M, van Leenders G, Verhofstad A, Rijpkema M . Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004; 20(2):279-87. DOI: 10.1002/jmri.20113. View

11.

Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P . Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2003; 31(3):317-24. DOI: 10.1007/s00259-003-1377-9. View

12.

Sarma A, Schottenfeld D . Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol. 2002; 20(1):3-9. DOI: 10.1053/suro.2002.30390. View

13.

Kotzerke J, Volkmer B, Neumaier B, Gschwend J, Hautmann R, Reske S . Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002; 29(10):1380-4. DOI: 10.1007/s00259-002-0882-6. View

14.

Ackerstaff E, Pflug B, Nelson J, Bhujwalla Z . Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61(9):3599-603. View

15.

Effert P, Bares R, Handt S, Wolff J, Bull U, Jakse G . Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996; 155(3):994-8. View

16.

Agus D, Golde D, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher H . Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res. 1998; 58(14):3009-14. View

17.

Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debre B . Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol. 2005; 47(5):582-6. DOI: 10.1016/j.eururo.2005.01.015. View

18.

Hara T, Kosaka N, Kishi H . PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998; 39(6):990-5. View

19.

Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N . Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001; 28(2):117-22. DOI: 10.1016/s0969-8051(00)00195-5. View

20.

de Jong I, Pruim J, Elsinga P, Vaalburg W, Mensink H . Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol. 2002; 42(1):18-23. DOI: 10.1016/s0302-2838(02)00129-x. View